--- title: "ARO-INHBE and the Activin E/ALK7 Pathway: Arrowhead's RNAi Bet on Silencing a Fat-Storage Gene to Supercharge Obesity Treatment (August 29, 2026) | PepTracker Pro Blog" url: https://peptrackerpro.com/blog/aro-inhbe-arrowhead-inhbe-activin-e-galnac-sirna-rnai-obesity-visceral-fat-liver-fat-body-composition-tirzepatide-combination-aro-alk7-acvr1c-genetically-validated-phase-1-2a-august-29-2026 description: "Human genetics said it should work: people born with rare loss-of-function INHBE variants carry less abdominal fat and get diabetes far less often. Arrowhead's ARO-INHBE is an RNAi therapy that silences that same gene in the liver to lower the hepatokine Activin E - and in early Phase 1/2a data it roughly doubled weight loss and tripled visceral, total and liver fat reduction on top of tirzepatide. Here is what the data show, why body composition matters more than the scale, and the big caveats behind the small numbers." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) Research & Compounds Research & Compounds # ARO-INHBE and the Activin E/ALK7 Pathway: Arrowhead's RNAi Bet on Silencing a Fat-Storage Gene to Supercharge Obesity Treatment (August 29, 2026) PepTracker Pro Research Team August 29, 2026 8 min read ## Table of Contents - A new way to attack obesity: silence a fat-storage gene - What ARO-INHBE is (and what an siRNA does) - The genetics that de-risked the target - Activin E and the ALK7 pathway - Phase 1/2a interim data: monotherapy - Adding it to tirzepatide: doubling weight loss, tripling fat loss - ARO-ALK7: silencing a gene inside fat cells - Why body composition matters more than the scale - The important caveats - Where this fits in the obesity pipeline ## A new way to attack obesity: silence a fat-storage gene Almost every obesity medicine making headlines works on appetite - GLP-1 and GLP-1/GIP drugs like semaglutide and tirzepatide dial down hunger and slow the gut. ARO-INHBE, an investigational therapy from Arrowhead Pharmaceuticals, takes a completely different route. Instead of changing how much you want to eat, it changes how the body stores fat, by switching off a single gene in the liver. That gene, INHBE, makes a hormone-like protein called Activin E, and a growing body of human genetics suggests that people who make less of it are simply built to carry fat in healthier places. ARO-INHBE is Arrowhead's attempt to reproduce that genetic good fortune with a drug - and its first clinical data, reported in January 2026, were striking enough to put the Activin E pathway on the map for obesity. ## What ARO-INHBE is (and what an siRNA does) ARO-INHBE is an RNA-interference (RNAi) medicine. RNA interference is a natural process cells use to silence genes: a short piece of double-stranded RNA called a small interfering RNA (siRNA) guides the cell's machinery to chop up the messenger RNA of a specific gene before it can be turned into protein. Arrowhead builds these siRNAs on its Targeted RNAi Molecule (TRiM) platform and attaches a sugar tag called GalNAc that docks onto receptors found almost exclusively on liver cells. The result is a drug that, after a subcutaneous injection, is soaked up by the liver and told to do one thing: stop making Activin E. Because RNAi produces deep, durable gene knockdown, the effect can last for weeks to months, allowing infrequent dosing - the same approach behind approved cardiometabolic siRNAs such as inclisiran (for cholesterol) and Arrowhead's own plozasiran and zodasiran (for triglycerides and lipids). ## The genetics that de-risked the target The reason anyone is excited about Activin E is that nature already ran the experiment. In 2022, two large exome-sequencing studies published in Nature Communications - together spanning hundreds of thousands of people, including an analysis of roughly 362,679 individuals - found that rare loss-of-function variants in the INHBE gene are associated with a lower waist-to-hip ratio, meaning a healthier, less abdominal pattern of fat. Carriers also had about 28% lower odds of type 2 diabetes and a better metabolic profile overall: lower triglycerides, higher HDL cholesterol, and lower fasting glucose. The most common of these variants cuts secreted Activin E by roughly 90%. In drug development, this kind of human genetic evidence is gold: it strongly suggests both that lowering Activin E is beneficial and that doing so is likely to be tolerable, because millions of people have effectively lived their whole lives with less of it. ## Activin E and the ALK7 pathway Activin E is a hepatokine - a signaling protein secreted by the liver - and it appears to act as a ligand in a pathway that tells fat tissue to store energy and hold onto it. A key partner in that pathway is a receptor on fat cells called ALK7, encoded by the gene ACVR1C, and variants that reduce ALK7 signaling are likewise linked to healthier fat distribution. In simple terms, the Activin E/ALK7 axis behaves like a brake on fat breakdown and a promoter of fat accumulation, especially the metabolically dangerous visceral fat packed around the organs. Releasing that brake - by lowering Activin E - is expected to increase lipolysis (fat breakdown) and reduce the enlargement and dysfunction of fat cells. Arrowhead is targeting both ends of the axis: ARO-INHBE silences the liver gene that makes the signal, while a companion drug, ARO-ALK7, silences the receptor gene inside fat cells themselves. ## Phase 1/2a interim data: monotherapy The ARO-INHBE trial (AROINHBE-1001, NCT06700538) is an early-stage, dose-escalating Phase 1/2a study in adults with obesity. On its own, ARO-INHBE did what it was designed to do. A single subcutaneous dose reduced blood levels of Activin E in a dose-dependent way, with a mean maximum reduction of about 85% after a 400 mg dose and a maximum observed reduction of about 94% - confirming deep, durable target engagement. That biology translated into changes in body composition: at week 16, a single dose reduced visceral fat by about 9.9% and liver fat by about 38%, while actually increasing total lean tissue by about 3.6%. With two doses, visceral fat fell by about 15.6% (placebo-adjusted) by week 24. The gain in lean tissue is worth pausing on, because loss of muscle is one of the recurring criticisms of appetite-driven weight loss. ## Adding it to tirzepatide: doubling weight loss, tripling fat loss The most attention-grabbing results came from combining ARO-INHBE with tirzepatide, the approved GLP-1/GIP dual agonist, in obese patients who also had type 2 diabetes - a group that typically loses less weight on incretin drugs. Two doses of ARO-INHBE (400 mg) added to tirzepatide produced roughly a two-fold greater weight loss at week 16: about -9.4% versus -4.8% for tirzepatide plus placebo. On MRI at week 12, the fat reductions were roughly tripled versus tirzepatide alone - visceral fat down 23.2% versus 7.4%, total fat down 15.4% versus 5.3%, and relative liver fat down a dramatic 76.7% versus 20%. In plain terms, adding an experimental gene-silencing injection to a leading obesity drug appeared to roughly double the scale weight loss and roughly triple the loss of the fat that matters most for metabolic health. Early safety was described as generally well tolerated, with mostly mild side effects, gastrointestinal rates similar to tirzepatide alone, and one serious adverse event (a limb abscess) judged unrelated to the drug. ## ARO-ALK7: silencing a gene inside fat cells Alongside ARO-INHBE, Arrowhead reported data on ARO-ALK7, which targets the other half of the pathway. This is a genuine technical milestone: ARO-ALK7 was described as the first RNAi therapeutic to silence an adipocyte-expressed gene in humans. Reaching fat cells with an siRNA is much harder than reaching the liver, and the company reported a mean reduction of about 88% (maximum about 94%) in ALK7 messenger RNA in adipose tissue at the 200 mg dose by week 8. A single dose of ARO-ALK7 also produced a placebo-adjusted visceral-fat reduction of about 14.1% by week 8, with no serious adverse events reported. Together, ARO-INHBE and ARO-ALK7 give Arrowhead two shots at the same fat-storage biology - one from the liver, one from the fat cell - and provide the first direct human tests of the Activin E/ALK7 axis as a drug target. ## Why body composition matters more than the scale It is tempting to reduce obesity drugs to a single number on a bathroom scale, but where fat sits and what happens to muscle matter enormously. Visceral fat - the fat wrapped around the liver, pancreas and intestines - is far more strongly tied to insulin resistance, fatty liver disease and cardiovascular risk than fat under the skin. Liver fat, likewise, is central to metabolic dysfunction-associated steatotic liver disease (MASLD). A therapy that preferentially strips visceral and liver fat could therefore improve metabolic health out of proportion to its effect on total weight. On the other side of the ledger, incretin drugs cause meaningful loss of lean mass along with fat, which worries clinicians about long-term strength and metabolic rate. ARO-INHBE's early signal - big cuts in visceral and liver fat, with lean tissue preserved or slightly increased on monotherapy - is precisely the profile the field has been hoping a next-generation add-on could deliver. ## The important caveats None of this is proven, and the numbers behind the headlines are tiny. The combination results rest on as few as three to four participants per arm, which is far too small to be certain that the doubled and tripled effects will hold up in larger studies. These are interim data from an early Phase 1/2a program, not results from a completed, randomized outcomes trial; there is no Phase 3 data, and no regulator has reviewed ARO-INHBE for anything. The early safety picture looked clean, but the long-term consequences of chronically lowering Activin E - a hormone involved in broad metabolic regulation - simply are not known yet, and short trials cannot rule out surprises. ARO-INHBE is investigational, available only inside clinical trials, and is not a supplement or a research chemical; anything sold under its name outside a regulated trial is unverified and unsafe. Genetic validation lowers the risk of a target, but it does not guarantee that a drug hitting that target will be safe and effective at scale. ## Where this fits in the obesity pipeline ARO-INHBE reflects two big shifts in how the industry is thinking about obesity. First, the future is increasingly seen as combinations: a backbone incretin like tirzepatide paired with an agent that attacks a complementary mechanism, rather than one drug doing everything. Because ARO-INHBE works through fat-storage biology instead of appetite, it is a natural combination partner - and its early data made that case vividly. Second, RNAi is moving from cholesterol and rare diseases squarely into cardiometabolic mainstream, joining Arrowhead's plozasiran and zodasiran and the broader wave of GalNAc siRNAs such as zilebesiran for blood pressure. Whether ARO-INHBE ultimately becomes a medicine will depend on larger, longer trials that confirm the fat-loss and body-composition benefits, establish durability and safety, and clarify how it should be dosed alongside incretins. For now, it stands as one of the most interesting early tests of a genetics-first, gene-silencing approach to reshaping the body - and a reminder that the next chapter of obesity treatment may be written in the liver and the fat cell, not just the appetite centers of the brain. Ready to track your peptide research? Open PepTracker Pro (https://app.peptrackerpro.com/) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. [1] Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates (ARO-INHBE and ARO-ALK7) - Arrowhead Investor Relations (January 6, 2026) Source (https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-interim-clinical-data-rnai) 2. [2] Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates - Business Wire (January 6, 2026) Source (https://www.businesswire.com/news/home/20260106676011/en/) 3. [3] RNAi-based therapeutics could treat obesity, results show - Drug Discovery World (January 7, 2026) Source (https://www.ddw-online.com/rnai-based-therapeutics-could-treat-obesity-results-show-39791-202601/) 4. [4] AROINHBE-1001: A Study of ARO-INHBE in Adult Participants With Obesity - ClinicalTrials.gov (NCT06700538) Source (https://clinicaltrials.gov/study/NCT06700538) 5. [5] Deaton AM, et al. Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity - Nature Communications (2022) Source (https://www.nature.com/articles/s41467-022-31757-8) 6. [6] Akbari P, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes - Nature Communications (2022) Source (https://www.nature.com/articles/s41467-022-32398-7) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Read full research disclaimer → (https://peptrackerpro.com/research-disclaimer) ## Related Articles Research & Compounds cover image (https://peptrackerpro.com/blog/plozasiran-arrowhead-redemplo-apoc3-apolipoprotein-c-iii-rnai-sirna-triglycerides-familial-chylomicronemia-fcs-palisade-shasta-pancreatitis-severe-hypertriglyceridemia-august-11-2026) Research & Compounds ### Plozasiran (Redemplo): The apoC-III Silencer That Cuts Triglycerides ~80% and Slashes Pancreatitis - PALISADE, SHASTA-3 and SHASTA-4 (August 11, 2026) (https://peptrackerpro.com/blog/plozasiran-arrowhead-redemplo-apoc3-apolipoprotein-c-iii-rnai-sirna-triglycerides-familial-chylomicronemia-fcs-palisade-shasta-pancreatitis-severe-hypertriglyceridemia-august-11-2026) Extreme triglycerides can top 1,000 mg/dL and trigger life-threatening pancreatitis, and for decades there was almost nothing to offer. Plozasiran - an every-three-months RNAi injection that silences apoC-III - cut triglycerides by about 80% and sharply reduced pancreatitis events. It won FDA approval as Redemplo for familial chylomicronemia syndrome in November 2025, and July 2026 Phase 3 data now push it toward the far larger severe hypertriglyceridemia population. PepTracker Pro Team August 11, 2026 8 min read Read (https://peptrackerpro.com/blog/plozasiran-arrowhead-redemplo-apoc3-apolipoprotein-c-iii-rnai-sirna-triglycerides-familial-chylomicronemia-fcs-palisade-shasta-pancreatitis-severe-hypertriglyceridemia-august-11-2026) Research & Compounds cover image (https://peptrackerpro.com/blog/zilebesiran-alnylam-roche-genentech-angiotensinogen-agt-galnac-sirna-rnai-hypertension-blood-pressure-raas-kardia-1-kardia-2-kardia-3-zenith-cardiovascular-outcomes-august-14-2026) Research & Compounds ### Zilebesiran: The Twice-a-Year RNAi Shot That Silences Angiotensinogen to Lower Blood Pressure - KARDIA-1, KARDIA-2, KARDIA-3 and the Phase 3 ZENITH Outcomes Trial (August 14, 2026) (https://peptrackerpro.com/blog/zilebesiran-alnylam-roche-genentech-angiotensinogen-agt-galnac-sirna-rnai-hypertension-blood-pressure-raas-kardia-1-kardia-2-kardia-3-zenith-cardiovascular-outcomes-august-14-2026) Most blood-pressure drugs must be taken every day, and most patients never reach goal. Zilebesiran takes a different route: a GalNAc-siRNA injection given as rarely as twice a year that silences angiotensinogen - the single upstream protein behind the entire renin-angiotensin system - and lowers systolic blood pressure for up to 6 months from one dose. Here is what KARDIA-1, KARDIA-2 and KARDIA-3 showed, and what the 11,000-patient Phase 3 ZENITH outcomes trial is testing. PepTracker Pro Team August 14, 2026 8 min read Read (https://peptrackerpro.com/blog/zilebesiran-alnylam-roche-genentech-angiotensinogen-agt-galnac-sirna-rnai-hypertension-blood-pressure-raas-kardia-1-kardia-2-kardia-3-zenith-cardiovascular-outcomes-august-14-2026) Research & Compounds cover image (https://peptrackerpro.com/blog/zodasiran-arrowhead-aro-ang3-angptl3-galnac-sirna-rnai-triglycerides-remnant-cholesterol-ldl-homozygous-familial-hypercholesterolemia-hofh-arches-2-gateway-yosemite-august-15-2026) Research & Compounds ### Zodasiran: The ANGPTL3-Silencing RNAi Injection That Lowers Triglycerides, Remnant Cholesterol and LDL - ARCHES-2, GATEWAY and the Phase 3 YOSEMITE Trial in Homozygous FH (August 15, 2026) (https://peptrackerpro.com/blog/zodasiran-arrowhead-aro-ang3-angptl3-galnac-sirna-rnai-triglycerides-remnant-cholesterol-ldl-homozygous-familial-hypercholesterolemia-hofh-arches-2-gateway-yosemite-august-15-2026) Most cholesterol drugs work through the LDL receptor - but some patients barely have one. Zodasiran, Arrowhead's investigational GalNAc-siRNA, silences the liver protein ANGPTL3 to cut triglycerides, remnant cholesterol and LDL through an LDL-receptor-independent route. Here is what the Phase 2b ARCHES-2 trial and the Phase 2 GATEWAY study in homozygous familial hypercholesterolemia showed, and what the pivotal Phase 3 YOSEMITE trial - enrollment completed in July 2026 - is testing. PepTracker Pro Team August 15, 2026 8 min read Read (https://peptrackerpro.com/blog/zodasiran-arrowhead-aro-ang3-angptl3-galnac-sirna-rnai-triglycerides-remnant-cholesterol-ldl-homozygous-familial-hypercholesterolemia-hofh-arches-2-gateway-yosemite-august-15-2026) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "ARO-INHBE and the Activin E/ALK7 Pathway: Arrowhead's RNAi Bet on Silencing a Fat-Storage Gene to Supercharge Obesity Treatment (August 29, 2026)", "description": "Human genetics said it should work: people born with rare loss-of-function INHBE variants carry less abdominal fat and get diabetes far less often. Arrowhead's ARO-INHBE is an RNAi therapy that silences that same gene in the liver to lower the hepatokine Activin E - and in early Phase 1/2a data it roughly doubled weight loss and tripled visceral, total and liver fat reduction on top of tirzepatide. Here is what the data show, why body composition matters more than the scale, and the big caveats behind the small numbers.", "datePublished": "2026-08-29", "dateModified": "2026-08-29", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/aro-inhbe-arrowhead-inhbe-activin-e-galnac-sirna-rnai-obesity-visceral-fat-liver-fat-body-composition-tirzepatide-combination-aro-alk7-acvr1c-genetically-validated-phase-1-2a-august-29-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "ARO-INHBE and the Activin E/ALK7 Pathway: Arrowhead's RNAi Bet on Silencing a Fat-Storage Gene to Supercharge Obesity Treatment (August 29, 2026)", "item": "https://peptrackerpro.com/blog/aro-inhbe-arrowhead-inhbe-activin-e-galnac-sirna-rnai-obesity-visceral-fat-liver-fat-body-composition-tirzepatide-combination-aro-alk7-acvr1c-genetically-validated-phase-1-2a-august-29-2026" } ] } ] ```